Investigational drug · Phase 3
MR-100A-01
Also called: Transdermal contraceptive delivery system
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Contraception.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "MR-100A-01"
First trial start
2021
Oct 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MR-100A-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Contraception
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "MR-100A-01" as an intervention, largest first.
- Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesPivotal-lookingCompleted
Mylan Technologies Inc.Industry
NCT05139121 · 1,320 participants · Start Oct 26, 2021 · Primary completion Jan 15, 2025
Drug: MR-100A-01 · For: Contraception
Sites: Mobile, Alabama; Mesa, Arizona; Phoenix, Arizona · 100 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Adhesion Evaluation of AG200-15: An Investigational Transdermal Contraceptive Delivery System.
Ocheltree T, Wittes J, Case J, et al. · Adv Ther 2019
- Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.
Sriprasert I, Stanczyk FZ, Archer DF · Expert Opin Pharmacother 2015
- Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer DF, Stanczyk FZ, Rubin A, et al. · Contraception 2012
- The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
Archer DF, Cullins V, Creasy GW, et al. · Contraception 2004
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.